Trial Profile
Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2012
Price :
$35
*
At a glance
- Drugs Milciclib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Sponsors Nerviano Medical Sciences
- 11 Jul 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 01 Aug 2011 New trial record